Advanced Diagnostics: Innovation, Reimbursement, And Coverage Challenges

Developers of novel advanced diagnostics tests face many challenges that dramatically constrain both innovation and the ability to provide new tests to clinicians and patients. Recently, planned changes in pricing detailed in the Protecting Access to Medicare Act of 2014, and new guidelines on evidence development have been put forward and in some cases adopted – will these recent changes address the challenges?

Advances in in vitro diagnostic testing have had a large and positive impact on the provision of health care over the past 15 years. This has been particularly apparent in oncology, starting in 1998 when Genentech Inc. launched its blockbuster treatment for HER2 positive breast cancer, Herceptin (trastuzumab). The development, approval, and launch of Herceptin occurred in conjunction with a companion test developed by Abbott Laboratories Inc.’s Abbott Diagnostics, and represented the first of a growing class of oncology drugs with companion diagnostics. Similarly, molecular prognostic tests such as Myriad Genetics Inc.’s BRACAnalysis test for BRCA1 and BRCA2 mutations can identify women at significantly elevated risk for developing breast or ovarian cancer, enabling at-risk women to consider medical management including more frequent monitoring procedures or risk-reducing surgery, when appropriate. Genomic Health Inc.’s Oncotype DX test helps guide treatment decisions by predicting the benefit of chemotherapy and the likelihood of recurrence.

Advances in diagnostics such as these are not limited exclusively to oncology. For example, noninvasive prenatal testing now allows at-risk...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.